Phaxiam Therapeutics Stock Gains 23% As It Extends Portfolio To Klebsiella Pneumoniae
Shares of Phaxiam Therapeutics S.A. (PHXM) gained over 23% on Tuesday morning after the company announced that it extended its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive … Read More